NY-ESO-1 TCR-T cell therapy with CRISPR-mediated knockout of TCR and PD-1 represents the first tumor-specific T cells with further genetic modifications tested in the clinic.358 Moreover, the CRISPR gene editing system allows for broader application of allogeneic T-cell therapy.359 When allogeneic products are depleted of their endogenous TCRs and HLA molecules, they become less likely to be rejected and have a reduction in GvHD potential.360 Alternatively, CRISPR-mediated screening systems have been applied in multiple clinical studies. The gene discussed is PDCD1; the disease is neoplasm.